Annual report pursuant to Section 13 and 15(d)

Intangible assets, net (Tables)

v3.22.2.2
Intangible assets, net (Tables)
12 Months Ended
May 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets

​

​

​

​

​

​

​

​

​

    

As of May 31,

​

​

2022

​

2021

Leronlimab (PRO 140) patent

​

$

3,500

​

$

3,500

ProstaGene, LLC intangible asset acquisition, net of impairment

​

 

—

​

​

2,926

Website development costs

​

 

20

​

 

20

Gross carrying value

​

​

3,520

​

​

6,446

Accumulated amortization, net of impairment

​

 

(3,388)

​

 

(4,793)

Total intangible assets, net

​

$

132

​

$

1,653